Back to Search

Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

  • Protocol Number: 202104143
  • Principal Investigator: Ward, Jeffrey
  • Cancer Types: Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).

Protocol Interventions

Biological: Neoantigen DNA vaccine, Drug: Durvalumab, Device: TDS-IM v2.0 Device, Procedure: Peripheral blood draws